ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 703

Autoimmune Hepatitis in Systemic Lupus Erythematosus

Doo-Ho Lim, Seung-Hyeon Bae, Soo Min Ahn, Seokchan Hong, Yong-Gil Kim, Chang-Keun Lee and Bin Yoo, Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: hepatitis and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Treatment and Management Studies

Session Type: Abstract Submissions (ACR)

Background/Purpose: Autoimmune Hepatitis (AIH) is a chronic progressive liver disease of unknown cause, characterized by circulating autoantibodies and hyperglobulinemia. Patients with AIH often have other autoimmune diseases such as autoimmune thyroiditis and ulcerative colitis. However, AIH accompanied by SLE (AIH-SLE overlap) is relatively rare condition. The aims of our study were to identify the distinct features of AIH-SLE overlap compared with primary AIH (PAIH) and to evaluate the factors related with outcome of AIH-SLE overlap.

Methods: From May. 1995 to Feb. 2014, the clinical data of 164 patients with PAIH and 23 patients with AIH-SLE overlap in a tertiary referral center were reviewed retrospectively. AlH was diagnosed if pretreatment or posttreatment score was above 9 or 11, according to AIH diagnostic scoring system of American Association for the Study of Liver Disease in 2002. Liver biopsy was performed in all AIH patients. SLE patients fulfilled at least 4 of the 1997 revised American College of Rheumatology criteria. Progression was defined as occurrence of liver cirrhosis (LC), hepatocellular carcinoma (HCC), liver transplantation (LT) or death from hepatic failure.

Results: The mean follow-up duration of AIH-SLE overlap and PAIH were 7.62 ± 4.13 years (range: 1.5 – 16) and 6.23 ± 4.21 (0.5 -17.5), respectively (Table 1). The age at AIH diagnosis was younger and initial serum IgG level was higher in AIH-SLE overlap (P < 0.005). There were no significant differences of histological findings and treatment strategy. Although proportion of overall progression was not different, severe progression such as HCC, LT or death only happened in PAIH patients. Among 23 patients of AIH-SLE overlap, 8 patients with progression showed higher serum IgG level (4077.38 ± 1641.02 mg/dl) compared to 15 patients without progression (2560.71 ± 932.24) (p=0.017). Furthermore, progression in AIH-SLE overlap was associated with serum IgG level of above 2 folds upper limit of normal (OR = 11.00, 95% CI = 1.420 – 85.201, P = 0.026).

Conclusion: The clinical course of AIH might be expected less aggressively in AIH-SLE overlap than PAIH. In addition, we could suggest that initial high level of serum IgG is a poor prognostic factor in patients with AIH-SLE overlap.

Table 1. Characteristics of AIH-SLE overlap and PAIH

Characteristic

AIH-SLE overlap (n= 23)

PAIH (n= 164)

Age at AIH diagnosis, years a

37.35 ± 12.55

49.98 ± 12.365

Sex, female (%)

23 (100)

149 (90.9)

Follow up, year

7.62 ± 4.13 (1.5 – 16)

6.23 ± 4.21 (0.5 – 17.5)

Other autoimmune disease (%)

4 (17.4)

21 (12.8)

Arthritis (%) a

9 (39.1)

27 (16.6)

Leukopenia (%)

3 (13.1)

25 (15.2)

Thrombocytopenia (%)

11 (47.8)

44 (26.8)

Protein, g/dl

8.40 ± 1.10

8.02 ± 4.07

Albumin, g/dl

3.42 ± 0.70

3.53 ± 0.2

AST, IU/l

402.43 ± 444.87

432.40 ± 552.15

ALT, IU/l

372.70 ± 514.39

355.34 ± 468.92

Alkaline phosphatase, IU/l

235.39 ± 176.12

165.20 ± 116.71

GGT, IU/l

168.24 ± 190.10

162.44 ± 250.23

Total bilirubin, mg/dl

5.99 ± 10.60

5.57 ± 6.83

Serum IgG, mg/dl a

3112.23 ± 1411.84

2419.23 ± 899.64

Autoantibody

anti nuclear antibody (%)

anti smooth muscle antibody (%)

anti LKM1 (%)

anti mitochondrial antibody (%)

23/23 (100)

8/21 (38.1)

1/17 (4.3)

0/22 (0)

141/162 (87)

42/161 (26.1)

0/136 (0)

6/160 (3.8)

Biopsy

  interface hepatitis (%)

  plasma cell infiltration (%)

  rosette (%)

  biliary change (%)

16 (69.6)

5 (21.7)

2 (8.7)

6 (26.1)

93 (56.7)

35 (21.3)

3 (1.8)

23 (14)

Progression at AIH diagnosis (%)

4/23 (17.4)

37/164 (22.5)

Progression after AIH diagnosis (%)

  liver cirrhosis

  hepatocellular carcinoma

  liver transplatation

  death from hepatic failure

4/19 (21.1)

4 (21.1)

0 (0)

0 (0)

0 (0)

45/127 (35.4)

38 (29.9)

1 (0.8)

3 (2.4)

3 (2.4)

a: p < 0.05

AST, Aspartate aminotransferase; ALT, Alanine transaminase; GGT, Gamma glutamyltransferse;

anti LKM1, anti Liver-Kidney-Microsomes antibody

 


Disclosure:

D. H. Lim,
None;

S. H. Bae,
None;

S. M. Ahn,
None;

S. Hong,
None;

Y. G. Kim,
None;

C. K. Lee,
None;

B. Yoo,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/autoimmune-hepatitis-in-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology